Lupin Ltd
NSE:LUPIN

Watchlist Manager
Lupin Ltd Logo
Lupin Ltd
NSE:LUPIN
Watchlist
Price: 2 169.45 INR 0.42% Market Closed
Market Cap: 989.7B INR
Have any thoughts about
Lupin Ltd?
Write Note

Operating Margin
Lupin Ltd

15.9%
Current
9%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
15.9%
=
Operating Profit
34B
/
Revenue
214.3B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
IN
Lupin Ltd
NSE:LUPIN
988.6B INR
16%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
US
Eli Lilly and Co
NYSE:LLY
749.1B USD
35%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK
44%
US
Johnson & Johnson
NYSE:JNJ
348B USD
28%
US
Merck & Co Inc
NYSE:MRK
251.1B USD
34%
CH
Roche Holding AG
SIX:ROG
200.1B CHF
32%
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP
21%
CH
Novartis AG
SIX:NOVN
171.5B CHF
31%
US
Pfizer Inc
NYSE:PFE
150.1B USD
22%
Country IN
Market Cap 988.6B INR
Operating Margin
16%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 749.1B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 2.7T DKK
Operating Margin
44%
Country US
Market Cap 348B USD
Operating Margin
28%
Country US
Market Cap 251.1B USD
Operating Margin
34%
Country CH
Market Cap 200.1B CHF
Operating Margin
32%
Country UK
Market Cap 161.8B GBP
Operating Margin
21%
Country CH
Market Cap 171.5B CHF
Operating Margin
31%
Country US
Market Cap 150.1B USD
Operating Margin
22%
No Stocks Found

Lupin Ltd
Glance View

Market Cap
988.6B INR
Industry
Pharmaceuticals

In the bustling landscape of the global pharmaceutical industry, Lupin Ltd. stands as a testament to the transformative power of innovation and strategic foresight. Founded in 1968 by Dr. Desh Bandhu Gupta, Lupin embarked on its journey with a clear vision: to deliver high-quality drugs at affordable prices. Over the years, it has adeptly navigated the complex world of pharmaceuticals to become a formidable player in the generics market. Its success is built on a robust portfolio that includes a diverse range of generic and branded formulations across many therapeutic segments such as cardiovascular, diabetology, asthma management, and anti-tuberculosis. The company prioritizes intensive research and development, paving the way for both the introduction of new generics and the development of advanced drug delivery systems. Such focus ensures Lupin maintains a competitive edge in both established markets like the United States and emerging markets across Asia and Africa. The company’s financial engine is powered largely by its extensive manufacturing and distribution capabilities, which are strategically positioned across the globe to maximize efficiency and meet demand. With state-of-the-art facilities in India supplemented by strategic acquisitions and partnerships overseas, Lupin produces a wide array of active pharmaceutical ingredients (APIs) and finished dosages, allowing it to capture value across different stages of the drug supply chain. This vertically integrated model not only enhances profit margins but also provides the agility to respond quickly to market shifts. Furthermore, Lupin's strategic emphasis on biosimilars and specialty drugs reinforces its commitment to innovation, unlocking new revenue streams amid growing global healthcare demands. As Lupin continues to expand its footprint, it remains anchored in its mission to improve healthcare outcomes, embodying a legacy where profitability harmoniously aligns with purpose.

LUPIN Intrinsic Value
1 503.56 INR
Overvaluation 31%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
15.9%
=
Operating Profit
34B
/
Revenue
214.3B
What is the Operating Margin of Lupin Ltd?

Based on Lupin Ltd's most recent financial statements, the company has Operating Margin of 15.9%.